FIELD: medicine.
SUBSTANCE: invention relates to a compound of the formula (IIa), its definably labeled derivatives, stereoisomers, racemic mixtures and pharmaceutically acceptable salts, a pharmaceutical composition based on them for the treatment, relief or prevention of a disorder or anomaly related to alpha-synuclein aggregates, a diagnostical composition based on them for use for visualizing alpha-synuclein aggregates, a method for data collection for the diagnostics or for the determination of predisposition to a disorder or anomaly related to alpha-synuclein aggregates, a method for data collection for tracking a residual disorder or predicting a reaction of a patient suffering from a disorder or anomaly related to alpha-synuclein aggregates, and to a method for the determination of a number of alpha-synuclein aggregates, where alpha-synuclein aggregates are Levi’s corpuscles and/or Levi’s neurites. In the general formula (IIa), 
is selected from a group consisting of 
, hydrogen and alkyl, where 
and alkyl can be attached in any available position, and where can be optionally substituted with one or more substituents RD; where 
is selected from 
where 
can be attached in any available position, and where can be optionally substituted with one or more substituents RE; in each case, RD is independently selected from a group consisting of halogen; in each case, RE is independently selected from a group consisting of heterocyclyl, where heterocyclyl can be optionally substituted with halogen.
EFFECT: development of new compounds of the formula (IIa) that can be used for the diagnostics, tracking of disease development or tracking of activity of drugs, group of disorders or anomalies related to alpha-synuclein aggregates, such as Parkinson’s disease, dementia with Levi’s corpuscles, Alzheimer’s disease, as well as for the treatment, relief or prevention of such disorders or anomalies.
(IIa)
18 cl, 10 tbl, 132 ex
| Title | Year | Author | Number |
|---|---|---|---|
| SUBSTITUTED N-ARYLBENZAMIDES AND RELATED COMPOUNDS FOR TREATING AMYLOID DISEASES AND SYNUCLEINOPATHY | 2005 |
|
RU2381213C2 |
| COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING BETA-AMYLOID DISEASES AND SYNUCLEINOPATHIES | 2009 |
|
RU2501792C2 |
| PROTOFIBRIL-BINDING ANTIBODIES AND USE THEREOF IN THERAPEUTIC AND DIAGNOSTIC METHODS FOR PARKINSON'S DISEASE, DEMENTIA WITH LEWY BODIES AND OTHER ALPHA-SYNUCLEINOPATHIES | 2011 |
|
RU2555526C2 |
| NEW COMPOSITIONS FOR PREVENTING OR TREATING DEGENERATIVE DISEASES OF CENTRAL NERVOUS SYSTEM | 2010 |
|
RU2581058C2 |
| ANTIVIRAL COMPOUNDS AND THEIR APPLICATION | 2010 |
|
RU2552533C2 |
| DRUG FOR INFLUENZA TREATMENT, CHARACTERIZED BY THE FACT THAT IT COMBINES A PER-DEPENDENT ENDONUCLEASE INHIBITOR AND A DRUG AGAINST FLU | 2016 |
|
RU2745071C2 |
| NOVEL COMPOUNDS FOR DIAGNOSING, TREATING AND PREVENTING DISEASES ASSOCIATED WITH ALPHA-SYNUCLEIN AGGREGATION | 2020 |
|
RU2822486C1 |
| ANTIRETROVIRAL COMPOUNDS AND USE THEREOF | 2010 |
|
RU2571662C2 |
| NITROGEN-CONTAINING TRICYCLIC DERIVATIVES HAVING HIV REPLICATION INHIBITION ACTIVITY | 2016 |
|
RU2720145C2 |
| ANTIVIRAL COMPOUNDS | 2009 |
|
RU2505540C2 |
